Published in Cancer Chemother Pharmacol on May 04, 2004
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant (2012) 0.92
Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer (2011) 0.80
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A (2008) 4.74
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions. Oncology (Williston Park) (2013) 2.84
Multiplexed detection of protein cancer markers with biobarcoded nanoparticle probes. J Am Chem Soc (2006) 2.64
Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park) (2010) 2.41
Peripheral T-cell lymphoma. Blood (2011) 2.11
Peripheral T-cell lymphoma: new therapeutic strategies. Oncology (Williston Park) (2013) 2.09
Cardiovascular toxicity of biologic agents for cancer therapy. Oncology (Williston Park) (2014) 2.09
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 2.06
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood (2005) 2.06
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2004) 2.03
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2003) 1.94
Acute promyelocytic leukemia: evolving therapeutic strategies. Blood (2002) 1.93
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant (2011) 1.88
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood (2008) 1.80
hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene (2003) 1.78
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol (2007) 1.72
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol (2003) 1.67
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2009) 1.62
Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell (2006) 1.61
Relationship between hip and knee strength and knee valgus during a single leg squat. J Appl Biomech (2006) 1.58
Hodgkin's lymphoma involving the CNS. J Clin Oncol (2007) 1.58
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol (2003) 1.55
T-cell non-Hodgkin lymphoma. Blood (2005) 1.53
Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res (2002) 1.48
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma (2012) 1.48
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma (2014) 1.47
miRNAs and their potential for use against cancer and other diseases. Future Oncol (2007) 1.47
Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report. Surg Neurol (2005) 1.46
Cancer metabolism as a therapeutic target. Oncology (Williston Park) (2013) 1.46
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol (2008) 1.44
Clinical Management Updates in Mantle Cell Lymphoma. Oncology (Williston Park) (2016) 1.43
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Oncology (Williston Park) (2015) 1.42
Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol (2004) 1.40
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1. Oncology (Williston Park) (2015) 1.40
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma (2012) 1.40
Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol (2004) 1.38
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2008) 1.36
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther (2007) 1.34
Clofarabine: past, present, and future. Leuk Lymphoma (2007) 1.31
Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc (2006) 1.27
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood (2011) 1.27
Glucose transporters in cancer metabolism. Curr Opin Oncol (2012) 1.25
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood (2005) 1.23
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood (2007) 1.19
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res (2006) 1.18
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2006) 1.15
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res (2003) 1.13
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol (2002) 1.13
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood (2012) 1.13
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol (2002) 1.12
Reovirus-based therapy for cancer. Expert Opin Biol Ther (2009) 1.11
Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc (2011) 1.11
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs (2006) 1.09
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood (2003) 1.09
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther (2006) 1.09
RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res (2003) 1.09
MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett (2008) 1.08
Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res (2007) 1.07
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood (2005) 1.06
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer (2011) 1.06
GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem (2011) 1.06
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol (2006) 1.05
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res (2003) 1.05
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics (2009) 1.05
Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol (2010) 1.04
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed Engl (2009) 1.04
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther (2005) 1.04
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol (2010) 1.04
Quadriceps femoris electromyogram during concentric, isometric and eccentric phases of fatiguing dynamic knee extensions. J Biomech (2006) 1.04
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood (2005) 1.03
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer (2005) 1.03
Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem (2009) 1.03
β-Catenin induces T-cell transformation by promoting genomic instability. Proc Natl Acad Sci U S A (2013) 1.03
RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol (2008) 1.02
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood (2010) 1.02
ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage. Ther Deliv (2012) 1.02
Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncology (Williston Park) (2007) 1.02
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma (2004) 1.02
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol (2005) 1.01
MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer (2014) 1.00